NVS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...

Stats
今日成交量	1.46M
平均成交量	1.63M
市值	190.64B
EPS	$0 ( 2024-04-23 )
下一个收益日期	( $1.850 ) 2024-07-16
Last Dividend	$3.47 ( 2023-03-09 )
Next Dividend	$0 ( N/A )
P/E	22.15
ATR14	$0.0230 (0.02%)

音量相关性

長: -0.67 (moderate negative)

短: -0.82 (strong negative)

Signal:(23.382) Be Aware. Possible trading coming up! (swing)

Novartis AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Novartis AG 相关性 - 货币/商品

-0.04
( neutral )

0.12
( neutral )

0.00
( neutral )

-0.40
( neutral )

-0.11
( neutral )

-0.51
( weak negative )

Novartis AG 财务报表

Annual	2023
营收:	$46.66B
毛利润:	$34.19B (73.27 %)
EPS:	$7.15

FY	2023
营收:	$46.66B
毛利润:	$34.19B (73.27 %)
EPS:	$7.15

FY	2022
营收:	$51.83B
毛利润:	$36.34B (70.12 %)
EPS:	$3.19

FY	2021
营收:	$52.88B
毛利润:	$37.01B (69.99 %)
EPS:	$10.71

Financial Reports:

No articles found.

Novartis AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$3.47 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novartis AG Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.42 - Stable (8.45%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.966	2000-11-14
Last Dividend	$3.47	2023-03-09
Next Dividend	$0	N/A
Payout Date	2023-03-20
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$44.60	--
Avg. Dividend % Per Year	2.46%	--
Score	4.08	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.42
Div. Directional Score	7.88	--

Next Divdend (Est)
(2025-01-10)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

4.08

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2000	$0.966	2.96%
2001	$0.450	1.12%
2002	$0.468	1.46%
2003	$0.627	1.89%
2004	$0.722	1.57%
2005	$0	0.00%
2006	$0.801	1.50%
2007	$0.969	1.67%
2008	$1.319	2.42%
2009	$1.541	3.11%
2010	$1.780	3.38%
2011	$2.11	3.56%
2012	$2.20	3.78%
2013	$2.27	3.56%
2014	$2.44	3.10%
2015	$2.52	2.73%
2016	$2.47	2.88%
2017	$2.46	3.38%
2018	$2.67	3.15%
2019	$2.57	3.06%
2020	$3.04	3.20%
2021	$3.38	3.58%
2022	$3.36	3.82%
2023	$3.47	3.76%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.307	1.500	3.86	5.79	[0 - 0.5]
returnOnAssetsTTM	0.162	1.200	4.61	5.54	[0 - 0.3]
returnOnEquityTTM	0.346	1.500	7.27	10.00	[0.1 - 1]
payoutRatioTTM	0.342	-1.000	6.58	-6.58	[0 - 1]
currentRatioTTM	0.903	0.800	-0.485	-0.388	[1 - 3]
quickRatioTTM	0.613	0.800	-1.102	-0.881	[0.8 - 2.5]
cashRatioTTM	0.323	1.500	9.31	10.00	[0.2 - 2]
debtRatioTTM	0.273	-1.500	5.45	-8.17	[0 - 0.6]
interestCoverageTTM	12.32	1.000	6.55	6.55	[3 - 30]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.96	2.00	7.52	10.00	[0 - 20]
debtEquityRatioTTM	0.649	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.726	1.000	1.237	1.237	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.534	1.000	8.14	8.14	[0.2 - 2]
assetTurnoverTTM	0.526	0.800	9.83	7.86	[0.5 - 2]
Total Score				10.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.346	2.50	8.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.96	2.00	8.35	10.00	[0 - 30]
dividendYielPercentageTTM	3.88	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.73	2.00	7.76	10.00	[0 - 30]
payoutRatioTTM	0.342	1.500	6.58	-6.58	[0 - 1]
pegRatioTTM	-3.02	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.277	1.000	5.57	0	[0.1 - 0.5]
Total Score				5.42

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.